

Application. No.: 09/914,088  
Docket No. B45172

**Amendments to the Claims**

42. (Currently Amended) A peptide, or mimotope thereof of less than 100 amino acids in length, comprising an isolated surface exposed epitope of a[[the]] Cε2 domain of IgE, wherein said surface exposed epitope of Cε2 is P1 (SEQ ID NO. 1), or a mimotope thereof.

43. (Cancelled)

44. (Withdrawn) A peptide as claimed in claim 42 wherein the surface exposed epitope of Cε2 is P2 (SEQ ID NO. 2), or a mimotope thereof.

45. (Withdrawn) A peptide as claimed in claim 42 wherein the surface exposed epitope of Cε2 is P3 (SEQ ID NO. 3), or a mimotope thereof.

46. (Withdrawn) A peptide as claimed in claim 42 wherein the surface exposed epitope of Cε2 is P4 (SEQ ID NO. 4), or a mimotope thereof.

47. (Withdrawn) A peptide as claimed in claim 42 wherein the surface exposed epitope of Cε2 is P5 (SEQ ID NO. 5), or a mimotope thereof.

48. (Withdrawn) A peptide as claimed in claim 42 wherein the surface exposed epitope of Cε2 is P6 (SEQ ID NO. 6), or a mimotope thereof.

49. (Withdrawn) A peptide as claimed in claim 42 wherein the surface exposed epitope of Cε2 is P7 (SEQ ID NO. 7), or a mimotope thereof.

50. (Withdrawn) A mimotope as claimed in claim 42 wherein the mimotope is a peptide.

51. (Currently Amended) The[[A]] peptide, or mimotope thereof as claimed in claim 42, wherein the isolated epitope is derived from a loop structure of the Cε2 domain of IgE.

52. (Currently Amended) The[[A]] peptide, or mimotope thereof as claimed in claim 51, wherein the loop structure of the Cε2 domain of IgE is a[[the]] A-B or a[[the]] C-D loop.

53. (Withdrawn) A peptide as claimed in claim 43 wherein the mimotope of P1 is a peptide of the general formula:  $h \times d \ h \ h \ a \ n \ a \ n \ x \ y$ ;  
wherein:  $h$  is a hydrophobic amino acid residue;  $d$  is an ionic bond donating amino acid residue;  $a$  is an acidic amino acid residue;  $n$  is an ionically neutral/non-polar amino acid residue; and  $x$  is an amino acid.

54. (Withdrawn) A peptide as claimed in claim 43, wherein the mimotope of P1 is a peptide of the general formula:

Application. No.: 09/914,088

Docket No. B45172

Q, X<sub>1</sub>, M, D, X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>

wherein X<sub>1</sub> is selected from V, I, L, M, F or A; X<sub>2</sub> is selected from D or E; and X<sub>3</sub> is selected from L, I, V, M, A or F.

55. (Withdrawn) A peptide as claimed in claim 43 wherein the mimotope of P1 is selected from the group consisting of P15q (SEQ ID NO. 11), PT1079 (SEQ ID NO. 13), PT1079GS (SEQ ID NO. 15), PT1078 (SEQ ID NO. 16), and PT15 (SEQ ID NO. 8).

56. (Withdrawn) A peptide as claimed in claim 44, wherein the mimotope of P2 is P16 (SEQ ID NO. 24).

57. (Withdrawn) A peptide as claimed in claim 45 wherein the mimotope of P3 is P17 (SEQ ID NO. 26).

58. (Currently Amended) An immunogen immunogenic composition for the treatment of allergy comprising the[[a]] peptide, or [[a ]]mimotope thereof as claimed in claim any one of claims 42 [[to 57]], additionally comprising a carrier molecule.

59. (Currently Amended) The[[An]] immunogen immunogenic composition as claimed in claim 58, wherein the carrier molecule is selected from Protein D or Hepatitis B core antigen.

60. (Currently Amended) An immunogen immunogenic composition for the treatment of allergy comprising the[[a]] peptide, or [[a ]]mimotope thereof as claimed in claim 42, wherein the immunogen immunogenic composition is a chemical conjugate of the peptide or [[the ]]mimotope thereof as claimed in claims 42 to 57, or wherein the immunogen is expressed as a fusion protein, and a carrier molecule.

61. (Currently Amended) The[[An]] immunogen immunogenic composition as claimed in claim 58, wherein the peptide, or peptide-mimotope thereof is presented within the primary sequence of the carrier.

62. (Currently Amended) The[[An]] immunogen immunogenic composition as claimed in claim 60, wherein the peptide, or peptide-mimotope thereof is presented within the primary sequence of the carrier.

63. (Currently Amended) A vaccine for the treatment of allergy comprising the[[an]] immunogen immunogenic composition as claimed in claim 58, further comprising an adjuvant.

Application. No.: 09/914,088  
Docket No. B45172

64. (Currently Amended) A vaccine for the treatment of allergy comprising the[[an]] immunogen immunogenic composition as claimed in claim 59, further comprising an adjuvant.

65. (Currently Amended) A vaccine for the treatment of allergy comprising the[[an]] immunogen immunogenic composition as claimed in claim 60, further comprising an adjuvant.

66. (Currently Amended) A vaccine for the treatment of allergy comprising the[[an]] immunogen immunogenic composition as claimed in claim 61, further comprising an adjuvant.

67. (Currently Amended) A vaccine for the treatment of allergy comprising the[[an]] immunogen immunogenic composition as claimed in claim 62, further comprising an adjuvant.

68. (Withdrawn) A ligand which is capable of recognizing a surface exposed epitope of the Cε2 domain of IgE, characterized in that the ligand is not PTmAb0005.

69. (Withdrawn) A ligand as claimed in claim 68, wherein the ligand is PTmAb0011 deposited under the Budapest Treaty patent deposit at ECACC on 8th March 1999 under Accession No. 99030805.

70. (Withdrawn) A pharmaceutical composition comprising a ligand which is capable of recognizing a surface exposed epitope of the Cε2 domain of IgE.

71. (Withdrawn) A pharmaceutical composition as claimed in claim 70 wherein the ligand is capable of recognizing the C-D Loop of the Cε2 domain of IgE.

72. (Withdrawn) A pharmaceutical composition as claimed in claim 71, wherein the ligand is a monoclonal antibody selected from PTmAb0005 or PTmAb0011.

73. (Withdrawn) A peptide which is recognized by PTmAb0005 or PTmAb0011.

74. (Withdrawn) An immunogen comprising a peptide as claimed in claim 73.

75. (Withdrawn) A method of manufacturing a vaccine comprising the manufacture of an immunogen as claimed in claim 58, and formulating the immunogen with an adjuvant.

76. (Withdrawn) A method of manufacturing a vaccine comprising the manufacture of an immunogen as claimed in claim 60, and formulating the immunogen with an adjuvant.

Application. No.: 09/914,088

Docket No. B45172

77. (Withdrawn) A method for treating a patient suffering from or susceptible to allergy, comprising the administration of a peptide as claimed in any one of claims 42 to 57, to the patient.

78. (Withdrawn) A method for treating a patient suffering from or susceptible to allergy, comprising the administration of a vaccine as claimed in claim 63 to the patient.

79. (Withdrawn) A method for treating a patient suffering from or susceptible to allergy, comprising the administration of a vaccine as claimed in claim 64 to the patient.

80. (Withdrawn) A method for treating a patient suffering from or susceptible to allergy, comprising the administration of a vaccine as claimed in claim 65 to the patient.

81. (Withdrawn) A method for treating a patient suffering from or susceptible to allergy, comprising the administration of a vaccine as claimed in claim 66 to the patient.

82. (Withdrawn) A method for treating a patient suffering from or susceptible to allergy, comprising the administration of a vaccine as claimed in claim 67 to the patient.

83. (Withdrawn) A method of treating a patient suffering from or susceptible to allergy comprising administration of a pharmaceutical composition as claimed in any one of claims 65 to 67, to the patient.

84. (New) An immunogenic composition for the treatment of allergy comprising the peptide, or mimotope thereof as claimed in claim 42, wherein the immunogenic composition is expressed as a fusion protein, and a carrier molecule.

85. (New) The immunogenic composition as claimed in claim 84, wherein the peptide, or mimotope thereof is presented within the primary sequence of the carrier.

86. (New) A vaccine for the treatment of allergy comprising the immunogenic composition as claimed in claim 84, further comprising an adjuvant.